Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eyepoint Pharmaceuticals Inc (NQ: EYPT )

11.32 -0.15 (-1.31%)
Streaming Delayed Price Updated: 10:25 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eyepoint Pharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
EyePoint Pharma Posts 12-Month Safety, Efficacy Data From Early-Stage Wet AMD Trial
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock
Via Benzinga
EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss
Via Benzinga
Meet The Company Bringing New Treatments For Serious Eye Issues To Market
Sign up for this week’s All Access giveaway here! 
Via Benzinga
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: EyePoint Pharmaceuticals Q2 Earnings
  EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Preview For EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a... 
Via Benzinga
7 Wildly Oversold Nasdaq Stocks to Buy Now
For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Recap: EyePoint Pharmaceuticals Q1 Earnings
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
EyePoint Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know
EyePoint Pharmaceuticals (NASDAQ:EYPT) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 49.1% to $0.28 during Thursday's regular session. As of 12:31 EST, Tonix Pharmaceuticals's stock is trading... 
Via Benzinga
Recap: EyePoint Pharmaceuticals Q4 Earnings
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.